These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 39090361)

  • 1. Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors.
    Sablin MP; Gestraud P; Jonas SF; Lamy C; Lacroix-Triki M; Bachelot T; Filleron T; Lacroix L; Tran-Dien A; Jézéquel P; Mauduit M; Barros Monteiro J; Jimenez M; Michiels S; Attignon V; Soubeyran I; Driouch K; Servant N; Le Tourneau C; Kamal M; André F; Bièche I
    Br J Cancer; 2024 Oct; 131(6):1060-1067. PubMed ID: 39090361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequencing Endocrine Therapy for Metastatic Breast Cancer: What Do We Do After Disease Progression on a CDK4/6 Inhibitor?
    Xi J; Ma CX
    Curr Oncol Rep; 2020 May; 22(6):57. PubMed ID: 32415339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elacestrant in ER+, HER2- Metastatic Breast Cancer with ESR1-Mutated Tumors: Subgroup Analyses from the Phase III EMERALD Trial by Prior Duration of Endocrine Therapy plus CDK4/6 Inhibitor and in Clinical Subgroups.
    Bardia A; Cortés J; Bidard FC; Neven P; Garcia-Sáenz J; Aftimos P; O'Shaughnessy J; Lu J; Tonini G; Scartoni S; Paoli A; Binaschi M; Wasserman T; Kaklamani V
    Clin Cancer Res; 2024 Oct; 30(19):4299-4309. PubMed ID: 39087959
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy of CDK4/6 inhibitor plus endocrine therapy in HR-positive/HER2-0 and HER2-low-positive metastatic breast cancer: a secondary analysis of PALOMA-2 and PALOMA-3 trials.
    Li H; Wu Y; Zou H; Koner S; Plichta JK; Tolaney SM; Zhang J; He YW; Wei Q; Tang L; Zhang H; Zhang B; Guo Y; Chen X; Li K; Lian L; Ma F; Luo S
    EBioMedicine; 2024 Jul; 105():105186. PubMed ID: 38861871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genomic alterations associated with resistance and circulating tumor DNA dynamics for early detection of progression on CDK4/6 inhibitor in advanced breast cancer.
    Kindt CK; Alves CL; Ehmsen S; Kragh A; Reinert T; Vogsen M; Kodahl AR; Rønlev JD; Ardik D; Sørensen AL; Evald K; Clemmensen ML; Staaf J; Ditzel HJ
    Int J Cancer; 2024 Dec; 155(12):2211-2222. PubMed ID: 39128978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Trends in HR+ metastatic breast cancer survival before and after CDK4/6 inhibitor introduction in the United States: a SEER registry analysis of patients with HER2- and HER2+ metastatic breast cancer.
    Brufsky A; Kwan ML; Sandin R; Stergiopoulos S; Karanth S; Cha-Silva AS; Makari D; Goyal RK
    Breast Cancer Res Treat; 2024 Nov; 208(2):223-235. PubMed ID: 39177933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EGFR and HER2 hyper-activation mediates resistance to endocrine therapy and CDK4/6 inhibitors in ER+ breast cancer.
    Belli S; Esposito D; Ascione CM; Messina F; Napolitano F; Servetto A; De Angelis C; Bianco R; Formisano L
    Cancer Lett; 2024 Jul; 593():216968. PubMed ID: 38788968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Complexity Predicts Resistance to Endocrine Therapy and CDK4/6 Inhibition in Hormone Receptor-Positive (HR+)/HER2-Negative Metastatic Breast Cancer.
    Davis AA; Luo J; Zheng T; Dai C; Dong X; Tan L; Suresh R; Ademuyiwa FO; Rigden C; Rearden TP; Clifton K; Weilbaecher K; Frith A; Tandra PK; Summa T; Haas B; Thomas S; Hernandez-Aya LF; Peterson LL; Wang X; Luo SJ; Zhou K; Du P; Jia S; King BL; Krishnamurthy J; Ma CX
    Clin Cancer Res; 2023 May; 29(9):1719-1729. PubMed ID: 36693175
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential through simplicity: thymidine kinase-1 as a biomarker for CDK4/6 inhibitors.
    McCartney A; Malorni L
    Br J Cancer; 2020 Jul; 123(2):176-177. PubMed ID: 32382111
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Cyclin-Dependent Kinase 4/6 Inhibitors on Circulating Cells in Patients with Metastatic Breast Cancer.
    Lobo-Martins S; Corredeira P; Cavaco A; Rodrigues C; Piairo P; Lopes C; Fraga J; Silva M; Alves P; Wachholz Szeneszi L; Barradas A; Castro Duran C; Antunes M; Nogueira-Costa G; Sousa R; Pinto C; Ribeiro L; Abreu C; Torres S; Quintela A; Mata G; Megías D; Ribot J; Serre K; Casimiro S; Silva-Santos B; Diéguez L; Costa L
    Cells; 2024 Aug; 13(16):. PubMed ID: 39195280
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer: a systematic review and meta-analysis.
    Masurkar PP; Prajapati P; Canedo J; Goswami S; Earl S; Bhattacharya K
    Curr Med Res Opin; 2024 Oct; 40(10):1753-1767. PubMed ID: 39305463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: a systematic review and meta-analysis of randomized trials.
    Messina C; Cattrini C; Buzzatti G; Cerbone L; Zanardi E; Messina M; Boccardo F
    Breast Cancer Res Treat; 2018 Nov; 172(1):9-21. PubMed ID: 30054831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disparities in receipt of 1-
    Pilehvari A; Kimmick G; You W; Bonilla G; Anderson R
    Breast Cancer Res; 2024 Oct; 26(1):144. PubMed ID: 39425174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. NOTCH and DNA repair pathways are more frequently targeted by genomic alterations in inflammatory than in non-inflammatory breast cancers.
    Bertucci F; Rypens C; Finetti P; Guille A; Adélaïde J; Monneur A; Carbuccia N; Garnier S; Dirix P; Gonçalves A; Vermeulen P; Debeb BG; Wang X; Dirix L; Ueno NT; Viens P; Cristofanilli M; Chaffanet M; Birnbaum D; Van Laere S
    Mol Oncol; 2020 Mar; 14(3):504-519. PubMed ID: 31854063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer.
    Cetin B; Wabl CA; Gumusay O
    Future Oncol; 2022 Mar; 18(9):1143-1157. PubMed ID: 35137602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
    Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
    Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapy after cyclin-dependent kinase inhibition in metastatic hormone receptor-positive breast cancer: Resistance mechanisms and novel treatment strategies.
    Sharifi MN; Anandan A; Grogan P; O'Regan RM
    Cancer; 2020 Aug; 126(15):3400-3416. PubMed ID: 32426848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of HER2-low expression on the efficacy of endocrine therapy with or without CDK4/6 inhibitor in HR-positive/HER2-negative metastatic breast cancer: A prospective study.
    Wu Y; Mo H; Xu H; Wang Y; Wang J; Ma F; Xu B
    Thorac Cancer; 2024 Apr; 15(12):965-973. PubMed ID: 38480513
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treating ER+ Breast Cancer with CDK4/6 Inhibitors.
    Cancer Discov; 2017 Aug; 7(8):OF4. PubMed ID: 28626036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.
    Goetz MP; Hamilton EP; Campone M; Hurvitz SA; Cortes J; Johnston S; Llombart-Cussac A; Kaufman PA; Toi M; Jerusalem G; Graham H; Wang H; Jansen VM; Litchfield LM; Martin M
    Clin Cancer Res; 2024 May; 30(10):2233-2244. PubMed ID: 37889120
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.